Are BCAAs Mere Biomarkers of Diabetes?

Andrew C. Shin

Department of Nutritional Sciences, College of Human Sciences, Texas Tech University, Lubbock, TX, USAUnited States

DOI: https://doi.org/10.17140/droj-3-e009 · Published 2017-01-04 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2017 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

DIABETES RESEARCH Editorial Are BCAAs Mere Biomarkers of Diabetes?

* *Corresponding author Andrew C. Shin, PhD * Assistant Professor Andrew C. Shin, PhD* Department of Nutritional Sciences College of Human Sciences Department of Nutritional Sciences, College of Human Sciences, Texas Tech University, Texas Tech University Lubbock, TX, USA Lubbock, TX, USA E-mail: andrew.shin@ttu.edu Branched-chain amino acids (BCAAs; ie. leucine, isoleucine, and valine) are essential Volume 3 : Issue 1 Article Ref. #: 1000DROJ3e009 amino acids we need to ingest through our diet.While circulating BCAA levels were first found to be elevated in obese individuals back in 1969 by Felig and colleagues,1 the potential role of BCAAs in obesity and diabetes development has been re-highlighted in the last decade. Us- Article History ing advanced metabolomic platforms, many independent investigators were able to reproduce nd Received: January 2nd, 2017 the earlier finding and further demonstrate that not only plasma BCAAs, but also their par- rd Accepted: January 3rd, 2017 tially oxidized intermediates such as α-keto acids and short-chain (C3-C5) acylcarnitines are th 2-9 Published: January 4 , 2017 increased in obese or insulin resistant/diabetic individuals, including Caucasians and Asians. Moreover, plasma BCAAs are found to be the earliest and the most predictive marker for future risk of diabetes,10 and elevated plasma leucine levels precede the development of fatty liver,11 Citation suggesting that circulating leucine is a predictive marker of hepatic steatosis. Interestingly, Shin AC. Are BCAAs mere bio- plasma BCAAs and their derived short-chain acylcarnitines are effectively lowered by bariatric markers of diabetes? Diabetes 5,8,12,13 Res Open J. 2017; 3(1): e4-e8. surgery in obese and/or diabetic individuals. Whether this normalized BCAA metabolism doi: 10.17140/DROJ-3-e009 after RYGB surgery in morbidly obese patients contributes to improved insulin sensitivity and glycemic control or is just a secondary effect of the surgery needs to be examined further. Nonetheless, collectively these studies implicate a role of plasma BCAAs and their metabolites in the pathogenesis of insulin resistance and diabetes.

The unresolved question in the field today is whether or not they are mere biomark- ers or they are one of the potential culprits for derangement of glucose metabolism and de- velopment of obesity and insulin resistance/diabetes. While a number of studies demonstrate that either amino acid mixture or BCAA supplementation have beneficial effects on protein 14-25 turnover and muscle wasting in patients with cirrhosis, kidney failure, cancer, or sepsis, mounting evidence suggests that amino acids/BCAAs or their metabolized keto acids lead to 7,26-28 29-32 hyperactivation of mTOR signaling, induction of oxidative stress, mitochondrial dys- 33,34 35,36 function, apoptosis, and more importantly, insulin resistance and/or impaired glucose 7,26-28,37-44 metabolism. Consistent with these findings, recent studies demonstrate that a BCAA metabolite elevated in diabetic individuals can drive vascular fatty acid transport in muscle and induce insulin resistance in mice44 and a defective muscle BCAA metabolism induces im- paired lipid metabolism and insulin resistance.45 On the other hand, deprivation of a single or all three BCAAs improves insulin sensitivity and glycemic control in either chow- or High-Fat 46-48 Diet (HFD)-fed, or genetically diabetic rodents. These findings strongly indicate not only a correlative, but also a causative role of circulating BCAAs and their oxidized intermediates in the development of insulin resistance and diabetes. As such, it is important to advance our understanding of BCAA regulatory mechanisms that would allow us to explain the reasons for high circulating levels of BCAAs found in obese and diabetic individuals.

The rise of plasma BCAAs in the obese and/or diabetic individuals may be simply because they take in more BCAAs due to their increased food consumption in general. But Copyright BCAAs levels are still higher in these individuals even after overnight fasting, or even when ©2017 Shin AC. This is an open ac- 9,10 cess article distributed under the they match the amount of protein intake with lean individuals.9,10 Alternatively, the higher plas- Creative Commons Attribution 4.0 ma BCAAs may be attributed to an increased release of endogenous BCAAs through protein International License (CC BY 4.0), breakdown or decreased BCAAs utilization in tissues due to decreased protein synthesis in which permits unrestricted use, these individuals, but both whole-body proteolysis and protein synthesis are not different be- distribution, and reproduction in any medium, provided the original tween diabetic and normal individuals, as they have been extensively reviewed by Tessari and work is properly cited. colleagues.49 Rather, the increased circulating BCAAs and their intermediates may be because of decreased or impaired BCAAs degradation in tissues like liver, muscle, and adipose tissue. This concept of impaired BCAAs metabolism in obesity and diabetes is supported by findings demonstrating decreased gene expressions of BCAA- degrading en- zymes in subcutaneous and omental fat tissues in obese twins compared to their lean monozygotic co-twins,50 decreased protein or activity of branched-chain α-keto acid dehydrogenase (BCKDH), the rate-limiting enzyme in BCAA degradation pathway, in livers 8 51 of obese ob/ob mice and diabetic fa/fa rats,8 in HFD fed rats and diet-induced obese men and monkeys,51 as well as in obese Pima Indians.52 The reasons for dysregulated BCAA metabolism in obese and diabetics are unclear. Systemic insulin lowers circulating BCAAs in normal healthy subjects but less so in obese and diabetic individuals, indicating insulin resistance as a major cause for 53-56 the elevated BCAA in obesity and diabetes. We have recently revealed for the first time the role of insulin in the regulation of BCAA metabolism by demonstrating that insulin dose-dependently lowers plasma BCAAs independent of glycemia via induction of hepatic BCAA catabolism.51 We further showed that this control of BCAA metabolism is mediated primarily through insulin action in the brain, and that impaired BCAA metabolism and the resultant higher plasma BCAA levels ensue in a state of central insulin resistance.51 Future studies examining the underlying mechanisms of BCAA-induced impairment of glucose or lipid partitioning, and the role of this novel neuroendocrine control of BCAA metabolism in either glucose or lipid homeostasis would give us new mecha- nistic insights into development of insulin resistance and diabetes and offer interventional or preventive therapeutic strategies to fight them.

CONFLICTS OF INTEREST The author declares no conflicts of interest.

References

1. Felig P, Marliss E, Cahill GF, Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969; 281(15): 811-816. doi: 10.1056/NEJM196910092811503 https://doi.org/10.1056/nejm196910092811503
2. AdamsSHHoppelCLLokKH. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009; 139(6): 1073-1081. doi: 10.3945/ jn.108.103754
3. KimJYParkJYKimOY. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J Proteome Res. 2010; 9(9): 4368-4375. doi: 10.1021/ pr100101p
4. KovesTRUssherJRNolandRC. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008; 7(1): 45-56. doi: 10.1016/j.cmet.2007.10.01310.1016/j.cmet.2007.10.013 https://doi.org/10.1016/j.cmet.2007.10.013
5. LaferrereBReillyDAriasS. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011; 3(80): 80-82. doi: 10.1126/scitranslmed.300204310.1126/scitranslmed.3002043 https://doi.org/10.1126/scitranslmed.3002043
6. MihalikSJGoodpasterBHKelleyDE. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010; 18(9): 1695-1700. doi: 10.1038/oby.2009.51010.1038/oby.2009.510 https://doi.org/10.1038/oby.2009.510
7. NewgardCBAnJBainJR. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009; 9(4): 311-326. doi: 10.1016/j.cmet.2009.02.00210.1016/j.cmet.2009.02.002 https://doi.org/10.1016/j.cmet.2009.02.002
8. ShePVan HornCReidTHutsonSMCooneyRNLynchCJ. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab. 2007; 293(6): E1552-E1563. doi: 10.1152/ajpendo.00134.200710.1152/ajpendo.00134.2007 https://doi.org/10.1152/ajpendo.00134.2007
9. TaiESTanMLStevensRD. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia. 2010; 53(4): 757-767. doi: 10.1007/s00125-009-1637-810.1007/s00125-009-1637-8 https://doi.org/10.1007/s00125-009-1637-8
10. WangTJLarsonMGVasanRS. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011; 17(4): 448-453. doi: 10.1038/nm.230710.1038/nm.2307 https://doi.org/10.1038/nm.2307
11. KaikkonenJEWurtzPSuomelaE. Metabolic profiling of fatty liver in young and middle-aged adults: Cross-sectional and prospective analyses of the Young Finns Study. Hepatology. 2016. doi: 10.1002/hep.2889910.1002/hep.28899 https://doi.org/10.1002/hep.28899
12. MutchDMFuhrmannJCReinD. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS One. 2009; 4(11): e7905. doi: 10.1371/journal.pone.000790510.1371/journal.pone.0007905 https://doi.org/10.1371/journal.pone.0007905
13. MagkosFBradleyDSchweitzerGG. Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. Diabetes. 2013; 62(8): 2757-2761. doi: 10.2337/db13-018510.2337/db13-0185 https://doi.org/10.2337/db13-0185
14. TsienCDavuluriGSinghD. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015; 61(6): 2018-2029. doi: 10.1002/hep.2771710.1002/hep.27717 https://doi.org/10.1002/hep.27717
15. MatsuokaSTamuraANakagawaraHMoriyamaM. Improvement in the nutritional status and clinical conditions of patients with liver failure using a liver diet combined with a branched chain amino acids-enriched elemental diet. Hepatogastroenterology. 2014; 61(133): 1308-1312. Web site. http://europepmc.org/abstract/med/25513087. Accessed January 1, 2017
16. ChinSEShepherdRWThomasBJ. Nutritional support in children with end-stage liver disease: A randomized crossover trial of a branched-chain amino acid supplement. Am J Clin Nutr. 1992; 56(1): 158-163. Web site. http://ajcn.nutrition.org/content/56/1/158.short. Accessed January 1, 2017
17. HabuDNishiguchiSNakataniS. Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: A randomized pilot trial. Hepatol Res. 2003; 25(3): 312-318. doi: 10.1007/4-431-27172-4_910.1007/4-431-27172-4_9 https://doi.org/10.1007/4-431-27172-4_9
18. TietzeINPedersenEB. Effect of fish protein supplementation on aminoacid profile and nutritional status in haemodialysis patients. Nephrol Dial Transplant. 1991; 6(12): 948-954. doi: 10.1093/ndt/6.12.94810.1093/ndt/6.12.948 https://doi.org/10.1093/ndt/6.12.948
19. IshiharaTIwasaMTanakaH. Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma. World J Gastroenterol. 2014; 20(10): 2673-2680. doi: 10.3748/wjg.v20.i10.267310.3748/wjg.v20.i10.2673 https://doi.org/10.3748/wjg.v20.i10.2673
20. KakazuEKondoYKogureT. Supplementation of branched-chain amino acids maintains the serum albumin level in the course of hepatocellular carcinoma recurrence. Tohoku J Exp Med. 2013; 230(4): 191-196. doi: 10.1620/tjem.230.19110.1620/tjem.230.191 https://doi.org/10.1620/tjem.230.191
21. ChoudryHAPanMKarinchAMSoubaWW. Branched-chain amino acid-enriched nutritional support in surgical and cancer patients. J Nutr Jan. 2006; 136(1 Suppl): 314S-318S. Web site. http://jn.nutrition.org/content/136/1/314S.long. Accessed January 1, 2017
22. TogoSTanakaKMoriokaD. Usefulness of granular BCAAs after hepatectomy for liver cancer complicated with liver cirrhosis. Nutrition. 2005; 21(4): 480-486. doi: 10.1016/j.nut.2004.07.01710.1016/j.nut.2004.07.017 https://doi.org/10.1016/j.nut.2004.07.017
23. BowerRHMuggia-SullamMVallgrenS. Branched chain amino acid-enriched solutions in the septic patient. A randomized, prospective trial. Ann Surg. 1986; 203(1): 13-20. Web site. http://journals.lww.com/annalsofsurgery/Citation/1986/01000/ Branched_Chain_Amino_Acid_Enriched_Solutions_in.3.aspx. Accessed January 1, 2017
24. Jimenez Jimenez FJ, Ortiz Leyba C, Morales Menedez S, Barros Perez M, Munoz Garcia J. Prospective study on the efficacy of branched-chain amino acids in septic patients. JPEN J Parenter Enteral Nutr. 1991; 15(3): 252-261. doi: 10.1177/0148607191015003252 https://doi.org/10.1177/0148607191015003252
25. Garcia-de-LorenzoAOrtiz-LeybaCPlanasM. Parenteral administration of different amounts of branch-chain amino acids in septic patients: Clinical and metabolic aspects. Crit Care Med. 1997; 25(3): 418-424. Web site. http://journals.lww.com/ ccmjournal/Abstract/1997/03000/Parenteral_administration_of_different_amounts_of.8.aspx. Accessed January 1, 2017
26. JeganathanSAbdullahiAZargarSMaedaNRiddellMCAdegokeOA. Amino acid-induced impairment of insulin sensitivity in healthy and obese rats is reversible. Physiol Rep. 2014; 2(7): e12067. doi: 10.14814/phy2.1206710.14814/phy2.12067 https://doi.org/10.14814/phy2.12067
27. TremblayFKrebsMDombrowskiL. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes. 2005; 54(9): 2674-2684. doi: 10.2337/diabetes.54.9.267410.2337/diabetes.54.9.2674 https://doi.org/10.2337/diabetes.54.9.2674
28. TremblayFMaretteA. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001; 276(41): 38052-38060. Web site. http://www.jbc.org/ content/276/41/38052.short. Accessed January 1, 2017
29. FunchalCLatiniAJacques-SilvaMC. Morphological alterations and induction of oxidative stress in glial cells caused by the branched-chain alpha-keto acids accumulating in maple syrup urine disease. Neurochem Int. 2006; 49(7): 640-650. doi: 10.1016/j.neuint.2006.05.00710.1016/j.neuint.2006.05.007 https://doi.org/10.1016/j.neuint.2006.05.007
30. Bridi R, Braun CA, Zorzi GK, et al. alpha-keto acids accumulating in maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats. Metab Brain Dis. 2005; 20(2): 155-167. doi: 10.1007/s11011- 005-4152-8 https://doi.org/10.1007/s11011-005-4152-8
31. LuGSunHSheP. Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells. J Clin Invest. 2009; 119(6): 1678-1687. doi: 10.1172/JCI38151DS110.1172/jci38151ds1 https://doi.org/10.1172/jci38151ds1
32. OyarzabalAMartinez-PardoMMerineroB. A novel regulatory defect in the branched-chain alpha-keto acid dehydrogenase complex due to a mutation in the PPM1K gene causes a mild variant phenotype of maple syrup urine disease. Hum Mutat. 2013; 34(2): 355-362. doi: 10.1002/humu.2224210.1002/humu.22242 https://doi.org/10.1002/humu.22242
33. AmaralAULeipnitzGFernandesCGSeminottiBSchuckPFWajnerM. Alpha-ketoisocaproic acid and leucine provoke mitochondrial bioenergetic dysfunction in rat brain. Brain Res. 2010; 1324: 75-84. doi: 10.1016/j.brainres.2010.02.01810.1016/j.brainres.2010.02.018 https://doi.org/10.1016/j.brainres.2010.02.018
34. LuGRenSKorgeP. A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development. Genes Dev. 2007; 21(7): 784-796. doi: 10.1101/ gad.1499107
35. JouvetPRustinPTaylorDL. Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: Implications for neurological impairment associated with maple syrup urine disease. Mol Biol Cell. 2000; 11(5): 1919-1932. doi: 10.1091/mbc.11.5.191910.1091/mbc.11.5.1919 https://doi.org/10.1091/mbc.11.5.1919
36. JouvetPKozmaMMehmetH. Primary human fibroblasts from a maple syrup urine disease patient undergo apoptosis following exposure to physiological concentrations of branched chain amino acids. Ann N Y Acad Sci. 2000; 926: 116-121. doi: 10.1111/j.1749-6632.2000.tb05604.x10.1111/j.1749-6632.2000.tb05604.x https://doi.org/10.1111/j.1749-6632.2000.tb05604.x
37. BalageMDupontJMothe-SatneyITesseraudSMosoniLDardevetD. Leucine supplementation in rats induced a delay in muscle IR/PI3K signaling pathway associated with overall impaired glucose tolerance. J Nutr Biochem. 2011; 22(3): 219-226. doi: 10.1016/j.jnutbio.2010.02.00110.1016/j.jnutbio.2010.02.001 https://doi.org/10.1016/j.jnutbio.2010.02.001
38. NicastroHZanchiNEda LuzCR. Effects of leucine supplementation and resistance exercise on dexamethasone-induced muscle atrophy and insulin resistance in rats. Nutrition. 2012; 28(4): 465-471. doi: 10.1016/j.nut.2011.08.00810.1016/j.nut.2011.08.008 https://doi.org/10.1016/j.nut.2011.08.008
39. ZanchiNEGuimaraes-FerreiraLde Siqueira-FilhoMA. Dose and latency effects of leucine supplementation in modulating glucose homeostasis: Opposite effects in healthy and glucocorticoid-induced insulin-resistance states. Nutrients. 2012; 4(12): 1851-1867. doi: 10.3390/nu412185110.3390/nu4121851 https://doi.org/10.3390/nu4121851
40. KrebsMKrssakMBernroiderE. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes. 2002; 51(3): 599-605. doi: 10.2337/diabetes.51.3.59910.2337/diabetes.51.3.599 https://doi.org/10.2337/diabetes.51.3.599
41. SahaAKXuXJLawsonE. Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes. 2010; 59(10): 2426-2434. doi: 10.2337/db09-187010.2337/db09-1870 https://doi.org/10.2337/db09-1870
42. BaumJIWashingtonTAShouseSA. Leucine supplementation at the onset of high-fat feeding does not prevent weight gain or improve glycemic regulation in male Sprague-Dawley rats. J Physiol Biochem. 2016; 72(4): 781-789. doi: 10.1007/s13105- 016-0516-210.1007/s13105-016-0516-2 https://doi.org/10.1007/s13105-016-0516-2
43. MogheiMTavajohi-FiniPBeattyBAdegokeOA. Ketoisocaproic acid, a metabolite of leucine, suppresses insulin-stimulated glucose transport in skeletal muscle cells in a BCAT2-dependent manner. Am J Physiol Cell Physiol. 2016; 311(3): C518-C527. doi: 10.1152/ajpcell.00062.201610.1152/ajpcell.00062.2016 https://doi.org/10.1152/ajpcell.00062.2016
44. JangCOhSFWadaS. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med. 2016; 22(4): 421-426. doi: 10.1038/nm.405710.1038/nm.4057 https://doi.org/10.1038/nm.4057
45. LerinCGoldfineABBoesT. Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism. Mol Metab. 2016; 5(10): 926-936. doi: 10.1016/j.molmet.2016.08.00110.1016/j.molmet.2016.08.001 https://doi.org/10.1016/j.molmet.2016.08.001
46. DuYMengQZhangQGuoF. Isoleucine or valine deprivation stimulates fat loss via increasing energy expenditure and regulating lipid metabolism in WAT. Amino Acids. 2012; 43(2): 725-734. doi: 10.1007/s00726-011-1123-810.1007/s00726-011-1123-8 https://doi.org/10.1007/s00726-011-1123-8
47. ChengYMengQWangC. Leucine deprivation decreases fat mass by stimulation of lipolysis in white adipose tissue and upregulation of uncoupling protein 1 (UCP1) in brown adipose tissue. Diabetes. 2010; 59(1): 17-25. doi: 10.2337/db09-092910.2337/db09-0929 https://doi.org/10.2337/db09-0929
48. WhitePJLapworthALAnJ. Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. Mol Metab. 2016; 5(7): 538-551. doi: 10.1016/j. molmet.2016.04.00610.1016/j.molmet.2016.04.006 https://doi.org/10.1016/j.molmet.2016.04.006
49. TessariPCecchetDCosmaA. Insulin resistance of amino acid and protein metabolism in type 2 diabetes. Clin Nutr. 2011; 30(3): 267-272. doi: 10.1016/j.clnu.2011.02.00910.1016/j.clnu.2011.02.009 https://doi.org/10.1016/j.clnu.2011.02.009
50. PietilainenKHNaukkarinenJRissanenA. Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med. 2008; 5(3): e51. doi: 10.1371/journal.pmed.005005110.1371/journal.pmed.0050051 https://doi.org/10.1371/journal.pmed.0050051
51. ShinACFasshauerMFilatovaN. Brain insulin lowers circulating BCAA levels by inducing hepatic BCAA catabolism. Cell Metab. 2014; 20(5): 898-909. doi: 10.1016/j.cmet.2014.09.00310.1016/j.cmet.2014.09.003 https://doi.org/10.1016/j.cmet.2014.09.003
52. LackeyDELynchCJOlsonKC. Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am J Physiol Endocrinol Metab. 2013; 304(11): E1175-E1187. doi: 10.1152/ ajpendo.00630.2012
53. SchauderPSchroderKMatthaeiDHenningHVLangenbeckU. Influence of insulin on blood levels of branched chain keto and amino acids in man. Metabolism. 1983; 32(4): 323-327. doi: 10.1016/0026-0495(83)90038-010.1016/0026-0495(83)90038-0 https://doi.org/10.1016/0026-0495(83)90038-0
54. TessariPNosadiniRTrevisanR. Defective suppression by insulin of leucine-carbon appearance and oxidation in type 1, insulin-dependent diabetes mellitus. Evidence for insulin resistance involving glucose and amino acid metabolism. J Clin Invest. 1986; 77(6): 1797-1804. Web site. http://www.jci.org/articles/view/112504. Accessed January 1, 2017
55. CaballeroBWurtmanRJ. Differential effects of insulin resistance on leucine and glucose kinetics in obesity. Metabolism. 1991; 40(1): 51-58. doi: 10.1016/0026-0495(91)90192-Y10.1016/0026-0495(91)90192-y https://doi.org/10.1016/0026-0495(91)90192-y
56. ForlaniGVanniniPMarchesiniGZoliMCiavarellaAPisiE. Insulin-dependent metabolism of branched-chain amino acids in obesity. Metabolism. 1984; 33(2): 147-150. doi: 10.1016/0026-0495(84)90127-610.1016/0026-0495(84)90127-6 https://doi.org/10.1016/0026-0495(84)90127-6